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Divergent Regulation of Actin 
Dynamics and Megakaryoblastic 
Leukemia-1 and -2 (Mkl1/2) by 
cAMP in Endothelial and Smooth 
Muscle Cells
Madeleine C. Smith1, Claire A. Hudson1, Tomomi E. Kimura1, Stephen J. White  2, Graciela B. 
Sala-Newby1, Andrew C. Newby  1 & Mark Bond1
Proliferation and migration of vascular smooth muscle cells (VSMCs) or endothelial cell (ECs) promote or 
inhibit, respectively, restenosis after angioplasty, vein graft intimal thickening and atherogenesis. Here 
we investigated the effects of cAMP-induced cytoskeletal remodelling on the serum response factor 
(SRF) co-factors Megakaryoblastic Leukemia-1 and -2 (MKL1 and MKL2) and their role in controlling 
VSMC and EC proliferation and migration. Elevation of cAMP using forskolin, dibutyryl-cAMP (db-
cAMP), BAY60-6583 or Cicaprost induced rapid cytoskeleton remodelling and inhibited proliferation 
and migration in VSMCs but not EC. Furthermore, elevated cAMP inhibited mitogen-induced nuclear-
translocation of MKL1 and MKL2 in VSMCs but not ECs. Forskolin also significantly inhibited serum 
response factor (SRF)-dependent reporter gene (SRE-LUC) activity and mRNA expression of pro-
proliferative and pro-migratory MKL1/2 target genes in VSMCs but not in ECs. In ECs, MKL1 was 
constitutively nuclear and MKL2 cytoplasmic, irrespective of mitogens or cAMP. Pharmacological or 
siRNA inhibition of MKL1 significantly inhibited the proliferation and migration of VSMC and EC. Our 
new data identifies and important contribution of MKL1/2 to explaining the strikingly different response 
of VSMCs and ECs to cAMP elevation. Elucidation of these pathways promises to identify targets for 
specific inhibition of VSMC migration and proliferation.
Vascular smooth muscle cell (VSMC) proliferation and migration contribute to restenosis after angioplasty, 
late vein graft failure and atherosclerosis1. Current-generation anti-mitotics, such as rapamycin and paclitaxel, 
increase thrombotic risk by impairing endothelial cell (EC) regrowth2. Clearly, there is a clinical requirement to 
identify signalling pathways that selectively inhibit VSMC proliferation and migration whilst sparing protective 
EC functions.
Elevated levels of 3′-5′ cyclic adenosine monophosphate (cAMP), an intracellular second messenger synthe-
sised by receptor-stimulated adenylyl cyclase, potently inhibit VSMC proliferation and migration in vitro and 
in vivo3–5 and reduce intimal lesion formation in animal models of vascular injury6. Crucially, cAMP also induces 
vascular protective effects in ECs, where it promotes barrier function7, and inhibits inflammation8, ROS gen-
eration9 and monocyte adhesion10. It is not surprising, therefore, that altered or aberrant cAMP signalling has 
been linked to numerous vascular pathologies, including angioplasty restenosis11, late vein graft failure12 and 
atherogenesis13.
Elevation of cAMP inhibits VSMC proliferation by downregulating multiple key cell-cycle intermediates4, 14–17  
but the upstream signalling mechanisms are incompletely characterised. The cAMP-activated transcription fac-
tor, CREB, has been implicated because forced expression of constitutively-active CREB mutants inhibit VSMC 
proliferation and migration18. However, selective PKA-agonists, which potently activate CREB, are insufficient 
to inhibit VSMC proliferation, implicating additional cAMP-sensitive pathways. We recently demonstrated that 
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the anti-mitotic activity of cAMP was associated with actin-cytoskeleton remodelling in response to inhibition 
of members of the Rho GTPases by cAMP19. Forced expression of active-mutants of RhoA or Rac1 prevent 
cAMP-induced growth arrest19, whereas RhoA and Rac1 inhibition mimic the effects of cAMP19, 20. By contrast, 
the effects of cAMP on proliferation and migration in ECs are less well defined. Elevated cAMP inhibits RhoA 
activity also in EC, but the effects on EC proliferation are controversial. Some studies report inhibitory effects21–23, 
whereas others report stimulatory effects24, 25.
Moreover, the mechanisms that sense changes in actin polymerisation and ultimately modulate responses in 
VSMCs and ECs have not been described. Some studies have linked actin dynamics to regulation of the MAPK 
pathway, proliferation and migration26–28 but effects of cAMP on proliferation and migration can be dissoci-
ated from cAMP-mediated MAPK inhibition15. The present study focusses on the MADS box transcription fac-
tor, serum response factor (SRF), which in conjunction with the co-activator, myocardin, modulates numerous 
smooth muscle specific contractile genes29. In NIH-3T3 fibroblasts, increased levels of actin monomer (G-actin) 
inhibits a specific subset of SRF target genes involved in proliferation and migration30, 31. This is mediated not 
by myocardin but by the related co-factors megakaryoblastic leukemia 1/2 (MKL1 and MKL2)30, 32. MKL1 
and MKL2 link actin cytoskeleton remodelling to gene transcription via RPEL domains that bind G-actin33. 
In the G-actin bound state, these co-factors are sequestered in the cytoplasm and unable to activate nuclear 
SRF-dependent transcription33. Interestingly, genome wide association studies (GWAS) analysis identified a SNP 
in the MKL1 promoter that was associated with increased incidence of coronary heart disease34 and MKL1 dele-
tion in mice causes a significant reduction in pathological intima formation35.
Here, we compare the effects of cAMP on proliferation, migration, actin cytoskeletal remodelling and MKL1/2 
activation in VSMCs and ECs. Our data demonstrate opposite effects of cAMP on proliferation and migration 
of VSMCs compared to ECs, which are related to divergent regulation of actin polymerisation and subsequent 
MKL-dependent gene transcription. These data show that differential regulation of MKL1/2 contributes to the 
divergent effects of cAMP in VSMCs and ECs and helps identify targets for selective intervention.
Results
Divergent effects of elevated cAMP on VSMC and EC proliferation and migration. We initially 
compared the effects of elevated cAMP on the proliferation and migration of VSMCs and ECs. The direct ade-
nylate-cyclase activator, forskolin, significantly increased intracellular levels of cAMP in either VSMC or EC, 
although levels were higher in VSMC (Supplement Fig. 1a and c). We therefore also stimulated cells with a fixed 
concentration (500 µM) of the cAMP analogue dibutyryl-cAMP. Stimulation of RaVSMCs or HuVSMCs with 
the adenylate-cyclase activator, forskolin, or the cAMP analogue db-cAMP resulted in a significant inhibition 
of serum stimulated proliferation, measured by BrdU incorporation (Supplement Fig. 2). In contrast, forskolin 
or db-cAMP resulted in a significant increase in proliferation of HUVECs and no significant change in HCAEC 
proliferation (Supplement Fig. 2). Stimulation of RaVSMCs or HuVSMCs with forskolin resulted in a significant 
inhibition of migration in real-time scratch wound assays (Supplement Fig. 3a,c). Stimulation of RaVMSC with 
db-cAMP also inhibited migration (Supplement Fig. 3b). However, the effect of db-cAMP on HuVSMC migration 
was very small and only just significant (Supplement Fig. 3d). In HUVECs and HCAECs, forskolin or db-cAMP 
did not significantly inhibit migration (Supplement Fig. 4a–d). Forskolin stimulation of HCAECs and db-cAMP 
stimulation of HUVECs actually resulted in a small delayed increase in wound closure. Activation of the aden-
osine A2B-receptor or the prostacyclin receptor, which are known to be coupled to adenylate cyclase activation, 
using BAY60-6583 or Cicaprost respectively, increased intracellular cAMP levels (Supplement Fig. 1b and d) 
and also inhibited proliferation and migration in VSMCs (Supplement Fig. 5a,b) but not HCAECs (Supplement 
Fig. 5c,d,e), These data demonstrate that elevated cAMP has divergent effects on proliferation and migration in 
VSMCs compared to ECs.
Divergent effects of elevated cAMP on VSMC and EC morphology and actin cytoskeleton 
remodelling. To investigate further the functional significance of cAMP-induced cytoskeletal changes on 
proliferation/migration in VSMCs and HUVECs, we performed detailed time-course experiments. In agreement 
with previous studies, stimulation of serum starved VSMCs with either forskolin or db-cAMP resulted in induc-
tion of a condensed, stellate morphology, characterised by reduced cell spreading (Fig. 1a,b and Supplement 
Fig. 6). We found that acquisition stellate morphology was evident after only 10 minutes (from 1696 ± 167 µm2 in 
control to 741 ± 160 µm2 for db-cAMP, p < 0.001, and to 731 ± 138 µm2 for forskolin, p < 0.001) and persisted for 
at least 240 minutes (Fig. 1a,b). In HUVECs, forskolin or db-cAMP stimulation did not induce stellate morphol-
ogy (Supplement Fig. 6) but instead resulted in small but significant (p < 0.05; two-way ANOVA) increase in cell 
spreading (Fig. 1c,d and Supplement Fig. 6).
Analysis of F-actin stress fibres in VSMCs using phalloidin staining demonstrated a rapid loss of F-actin 
within 10 minutes of forskolin stimulation that persisted for at least 60 minutes (Fig. 2a; left panel). Loss of 
F-actin implies impaired actin-polymerisation and increased actin monomer. To test this, we stained cells with 
Alexa-fluor-568-conjugated DNAse1, which specifically binds actin monomer36. DNAse1 staining in control 
cells was weak, indicating low levels of actin monomer, but rapidly increased (by 1.54 ± 0.167 fold; p < 0.05 after 
10 minutes and by 2.47 ± 0.27 fold; p < 0.001 after 60 minutes of forskolin stimulation; Fig. 2a; right panel and 
2B). To further confirm these changes in the actin cytoskeleton, we quantified levels of F- and G-actin using 
selective solubilisation of G-actin in Triton-X-100, as previously described37. This demonstrated that forskolin 
stimulation of VSMC resulted in a significant reduction in F-actin and a significant increase in G-actin (Fig. 2c).
In HUVECs, no reduction in stress fibres was detected after forskolin stimulation (Fig. 2d; left panels). On the 
contrary, forskolin stimulation resulted in a more intense staining of cortical actin stress fibres in the cell periph-
ery. No change in DNAse1 stained actin monomer was detected after forskolin stimulation (Fig. 2d; right panels 
and 2E). Quantification of F- and G-actin levels by selective Triton-X-100 solubilisation also did not detect any 
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significant change in F- or G-actin (Fig. 2f) Taken together, these data demonstrate that elevated cAMP induces 
rapid loss of F-actin stress fibres, increased actin monomer levels and a condensed stellate morphology in VSMCs 
but not in ECs.
Divergent effects of elevated cAMP on SRF-dependent gene expression in VSMCs and 
ECs. Given that the activity of SRF has been shown to depend on the level of actin-polymerisation in fibro-
blasts30, 31, we compared the activity of SRF in VSMCs and ECs in response to elevated cAMP. Stimulation of 
VSMCs with forskolin for 4 or 8 hours resulted in significant inhibition (to 0.82 ± 0.06 fold after 4 hours, p < 0.05 
and to 0.19 ± 0.06 fold after 8 hours, p < 0.001) of SRE-dependent luciferase reporter gene (SRE-LUC) activity 
(Fig. 3a). In contrast, SRE-LUC activity was not significantly different after 4 hours and significantly increased 
after 8 hours (to 1.61 ± 0.28 fold, p < 0.05) of forskolin stimulation in ECs (Fig. 3b). We next used RT-qPCR 
to quantify effects on endogenous SRF-target genes (CCN1, CTGF, ACTA2 and TPM1). Forskolin stimulation 
of VSMCs resulted in a significant reduction in mRNA levels of CCN1, CTGF, ACTA2 and TPM1 but not the 
house-keeping gene 36B4 (Fig. 3c). However, forskolin stimulation of ECs significantly increased mRNA levels 
of CCN1, CTGF, and TPM1. ACTA2 and 36B4 levels were not significantly different (Fig. 3d). We next quanti-
fied effects on CREB-dependent gene expression in order to investigate whether the observed divergent effects 
on SRF-dependent gene expression were simply due to generalised differences in cAMP responses. Forskolin 
stimulated CREB-dependent luciferase reporter (CREB-LUC) activity by a similar magnitude (approximately ten 
fold) and resulted in a rapid transient stimulation of NR4A mRNA, a known CREB-target gene, in both VSMCs 
and ECs (Fig. 3g and h). These data demonstrate divergent regulation of SRF activity, despite similar regulation of 
CREB activity by cAMP in VSMCs and ECs.
Divergent effects of adenosine, Cicaprost and elevated cAMP on MKL1 and MKL2 
cytoplasmic-nuclear shuttling in VSMCs and ECs. We next investigated the mechanisms underlying 
the divergent regulation of SRF activity by cAMP in VSMCs and ECs. Megakaryoblastic leukemia 1 (MKL1) and 
Megakaryoblastic leukaemia 2 (MKL2) are both SRF co-factors that contain N-terminal actin-binding RPEL 
domains, which in MKL1 have been shown to control cytoplasmic:nuclear shuttling, and hence MKL1:SRF activ-
ity, in an actin-dependent manner30. We therefore studied the regulation of MKL1 and MKL2 cytoplasmic:nuclear 
shuttling in response to elevated cAMP in VSMCs and ECs. MKL1 and MKL2 protein are expressed in RaVSMCs, 
Figure 1. Elevated cAMP inhibits cell spreading in VSMCs but not ECs. RaVSMCs (a and b; n = 3) and 
HUVECs (c and d; n = 3) were serum starved for 18 hours before stimulation with 25 µM forskolin (a and c) 
or 500 µM db-cAMP (b and d) in serum free conditions for the indicated times and total cell area assessed 
by image analysis of phase contrast images using ImageJ software. Water vehicle control is common to both 
conditions. *Indicates p < 0.05, ***indicates p < 0.001; Two way repeated measures ANOVA. $Indicates 
p < 0.05, $$indicates p < 0.01 $$$indicates p < 0.001 vs timepoint zero; One-way ANOVA with student Newman 
Kuels post test.
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HuVSMCs and HUVECs (Supplement Fig. 7). In quiescent VSMCs, MKL1 was predominantly cytoplasmic (only 
2.5 ± 1.3% of cells with nuclear MKL1) but rapidly translocated to the nucleus (70.4 ± 2.6% of cells with nuclear 
MKL1; p < 0.001 vs serum free) within 1 hour of serum stimulation (Fig. 4a and b). Importantly, stimulation with 
forskolin or db-cAMP completely prevented serum stimulated (Fig. 4) MKL1 nuclear localisation. A similar sig-
nificant inhibition of serum-induced nuclear localisation of endogenous MKL1 was detected by cell fractionation 
Figure 2. Elevated cAMP inhibits actin polymerisation in VSMCs but not ECs. RaVSMCs (a–c) and ECs (d–f) 
were serum starved for 4 hours before stimulation with 25 µM forskolin (FSK) in serum free conditions for 
the indicated times. Polymerised actin (F-actin) filaments and actin-monomer (G-actin) were detected using 
Phalloidin (Green) and DNAse 1 (Red) staining of paraformaldehyde fixed cells. DNAse1 staining of VSMCs 
(n = 6) and HUVECs (n = 5) was quantified by densitometric analysis (b and e, respectively). Quantification 
of F- and G- actin levels by Western blotting (c and f; cropped blots shown). *Indicates p < 0.05, ***indicates 
p < 0.001; one-way with replication ANOVA and Student Newman Keuls post-test. Bar indicates 50 µm.
www.nature.com/scientificreports/
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Figure 3. Elevated cAMP inhibits SRF-dependent transcription in VSMCs but not ECs. RaVSMCs (a; n = 3, e; 
n = 3) and HUVECs (b; n = 4, f; n = 7) were transfected with SRE-LUC (a,b) or CREB-LUC (e,f) and stimulated 
with 25 µM forskolin (FSK) for 4 or 8 hours in the presence of 5% serum and lysates assayed for luciferase 
activity. RaVSMCs (c,g) and HUVECs (d,h) were stimulated with 25 µM forskolin for 4 hours or the indicated 
times and mRNA levels of indicated genes quantified by RT-qPCR. *Indicates p < 0.05, **indicates p < 0.01, 
***indicates p < 0.001 relative to control; one-way with replication ANOVA Student Newman Keuls post-test.
Figure 4. Elevated cAMP inhibits MKL1 nuclear localisation in VSMCs but not ECs. RaVSMCs (a,b; 
n = 3) and HUVECs (c,d; n = 3) were infected with adenoviral vectors expressing GFP-MKL-1. Cells were 
serum starved for 4 hours before being stimulated for 1 hour with 10% FCS in the presence of either 25 µM 
forskolin (FSK) or 500 µM db-cAMP, as indicated. Cells were analysed for cellular localisation of MKL1 by 
fluorescence microscopy (a and c). Cellular localisation of MKL1 (classified as either nuclear, cytoplasmic or 
equally distributed between the cytoplasm and nucleus) was quantified by image analysis (b and d). Images 
are representative of at least three separate experiments. ***Indicates p < 0.0001 with respect to nuclear 
localisation; one-way with replication ANOVA and Student Newman Keuls post-test. Bar indicates 50 µm.
www.nature.com/scientificreports/
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and western blotting (Supplement Fig. 8). Furthermore, stimulation of VSMCs with BAY60-6583 or Cicaprost 
also significantly inhibited basal and serum induced nuclear localisation of MKL1 (Supplement Fig. 9).
In HUVECs and HCAECs, MKL1 was predominantly nuclear under serum starvation and remained nuclear 
after serum stimulation (Fig. 4c and d and Supplement Figs 10 and 11). MKL1 remained nuclear even after pro-
longed (18 hours) serum starvation (Supplement Fig. 11). Importantly, stimulation with forskolin or db-cAMP 
had no effect on MKL1 localisation in HUVECs (Fig. 4) or HCAECs (Supplement Fig. 11), with 100% of cells 
maintaining nuclear-localised MKL1, even after 18 hours of stimulation (Supplement Fig. 11). Elevation of 
endogenous cAMP with BAY60-6583 or Cicaprost also had no effect of the nuclear localisation of MKL1 in 
HCAECs (Supplement Fig. 10).
In quiescent VSMCs, MKL2 was exclusively cytoplasmic but was rapidly translocated to the nucleus within 
1 hour of serum stimulation (Fig. 5a and b). Stimulation with forskolin or db-cAMP completely suppressed the 
serum stimulated (Fig. 5a and b) nuclear localisation of MKL2. BAY60-6583 and Cicaprost also significantly 
inhibited serum stimulated and basal MKL2 nuclear localisation (Supplement Fig. 9d–f). In HUVECs, MKL2 
exhibited a constitutively-cytoplasmic localisation that was not significantly modulated by serum stimulation, 
with or without forskolin or db-cAMP co-stimulation (Fig. 5c and d).
Divergent roles of RhoA-actin signalling in cAMP-dependent regulation of MKL1 and MKL2 
in VSMCs. Our data demonstrated that cAMP-dependent reduction in actin-polymerisation and increased 
levels of actin monomer is associated with inhibition of MKL1 and MKL2 cytoplasmic:nuclear shuttling in 
VSMCs. Given that elevated cAMP has been linked to inhibition of RhoA-ROCK signalling, we tested the role 
of RhoA-ROCK and actin monomer in the regulation of MKL1 and MKL2 by cAMP. We initially asked if cAMP 
differentially modulates RhoA-ROCK signalling in VSMCs and ECs. Treatment of VSMCs and HUVECs with 
forskolin rapidly inhibited phosphorylation of the ROCK substrate, MYPT (Fig. 6a), indicating inhibition of 
RhoA-ROCK signalling in both cell types. Inhibition of RhoA-ROCK signalling using Y27632 significantly 
reversed serum induced nuclear translocation of MKL1 but not MKL2 in VSMC (Fig. 6b and c) suggesting that 
MKL1 is RhoA-ROCK-dependent and MKL2 is RhoA-ROCK independent in VSMC. Consistent with this, 
expression of a constitutively-active RhoA mutant (Ad:RhoAG14V) forced nuclear localisation of MKL1, which 
could not be overcome by forskolin (Fig. 6d). In contrast, the nuclear translocation of MKL2 and its inhibition 
by forskolin in VSMCs was not modulated by expression of constitutively-active RhoA (Fig. 6e) suggesting that 
nuclear exclusion of MKL2 by cAMP occurs independently of RhoA inhibition.
Figure 5. Elevated cAMP inhibits MKL2 nuclear localisation in VSMCs but not ECs RaVSMCs (a,b; 
n = 3) and HUVECs (c,d; n = 3) were infected with adenoviral vectors expressing GFP-MKL-2. Cells were 
serum starved for 4 hours before being stimulated for 1 hour with 10% FCS in the presence of either 25 µM 
forskolin (FSK) or 500 µM db-cAMP, as indicated. Cells were analysed for cellular localisation of MKL2 by 
fluorescence microscopy (a and c). Cellular localisation of MKL2 (classified as either nuclear, cytoplasmic or 
equally distributed between the cytoplasm and nucleus) was quantified by image analysis (b and d). Images 
are representative of at least three separate experiments. ***Indicates p < 0.0001 with respect to nuclear 
localisation; One-way with replication ANOVA and Student Newman Keuls post-test. Bar indicates 50 µm.
www.nature.com/scientificreports/
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Figure 6. Regulation of MKL-1 and -2 by RhoA and actin monomer in VSMCs. RaVSMCs and HUVECs 
were treated with 25 µM forskolin for indicated times and total cell lysates analysed for phosphorylated MYPT 
by western blotting (a; n = 1; cropped blots shown). RaVSMCs were serum starved for 4 hours and stimulated 
for 1 hour with 10% FCS ± 10 µM Y27632 and cellular localisation of MKL1 (b; n = 3) or MKL2 (c; n = 3) 
quantified (b; n = 3). RaVSMCs were infected with adenoviral vector expressing GFP-MKL1 (d; n = 3) or 
GFP-MKL2 (e; n = 3) together with either control virus (Ad:control) or virus expressing constitutively-active 
RhoA (Ad:RhoAG14V). Cells were serum starved for 4 hours before being stimulated for 1 hour with 10% 
FCS in the presence or absence of 25 µM forskolin and MKL-1 and -2 localisation quantified. HUVECs were 
serum starved for 4 hours before a 1 hour stimulation with 10% FCS ± 10 µM Y27632 and cellular localisation 
of MKL1 quantified (f; n = 3). MKL1 localisation in HUVECs that were serum starved for 4 hours before a 
1 hour stimulation with 10% FCS in the presence of 25 µM forskolin (FSK) and/or 10 µM NSC273766 (g; n = 3). 
www.nature.com/scientificreports/
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In HUVECs, Y27632 had no effect on the constitutively nuclear MKL1 (Fig. 6f) suggesting that MKL1 is 
RhoA-ROCK-independent in EC. We therefore tested the role of Rac1. Co-stimulation of HUVECs with forsko-
lin and the Rac1 inhibitor NSC273766 resulted in a significant reduction in nuclear MKL1 (Fig. 6g).
We next tested the role of increased actin-monomer (G-actin) in the cAMP-dependent regulation of MKL1 
and MKL2 in VSMCs. We depleted actin monomer levels using jasplakinolide, which promotes actin polymerisa-
tion, or cytochalasin-D, which sequesters actin monomers. Conversely, latrunculin-B, which inhibits actin polym-
erisation was used to elevate actin monomer. Latrunculin –B significantly reduced levels of F-actin and increased 
G-Actin, while Jasplakinolide significantly increased levels of F-actin and reduced G-Actin (Supplement Fig. 12). 
Co-stimulation with jasplakinolide or cytochalasin-D completely reversed the inhibitory effects of forskolin on 
MKL1 (Fig. 6h) and MKL2 (Fig. 6i) nuclear localisation. Stimulation with latrunculin-B induced an exclusively 
cytoplasmic localisation of both proteins. Taken together, these data indicate that cAMP-regulation of both MKL1 
and MKL2 is dependent on elevation of actin-monomer.
Regulation of proliferation and migration by MKL1 and MKL2 in VSMCs and ECs. Our data 
demonstrates that the anti-mitogenic and anti-migratory properties of cAMP in VSMCs are associated with inhi-
bition of MKL1 and MKL2 nuclear localisation. In ECs, by contrast, cAMP does not inhibit MKL1 nuclear local-
isation and does not inhibit proliferation or migration. The implication is that inhibition of MKL1 and/or MKL2 
nuclear localisation may underlie the anti-mitogenic and anti-migratory properties of cAMP in VSMCs. To test 
this further, we analysed the function of MKL1 and MKL2 in VSMCs and ECs using pharmacological inhibition 
and gene-silencing. Treatment of cells with the second-generation MKL-inhibitor, CCG203971, resulted in a sig-
nificant inhibition of cell proliferation, measured by BrdU incorporation in human and rat VSMCs, HUVECs and 
HCAECs (Fig. 7a). We validated the effects of CCG203971 using MKL1 and MKL2 silencing. Transient transfec-
tion of VSMC with MKL1/2 siRNA reduced MKL1 and MKL2 protein, without affecting GAPDH (Supplement 
Fig. 13a). Adenoviral-mediated expression of MKL1 shRNA in HUVECs also reduced MKL1 protein without 
affecting GAPDH (Supplement Fig. 13b). Silencing of MKL1, MKL2 or simultaneous silencing of both in VSMCs 
also significantly inhibited VSMC proliferation (Fig. 7b). In ECs, silencing of MKL1 alone (since this was the 
only MKL-factor displaying nuclear localisation in these cells) also significantly inhibited proliferation (Fig. 7c). 
Treatment with CCG203971 also significantly inhibited migration of VSMCs (Fig. 7d and e), HUVECs (Fig. 7f) 
and HCAECs (Supplement Fig. 14). Dual silencing of MKL1 plus MKL2 or individual silencing of MKL1, but not 
MKL2 significantly inhibited VSMC migration (Fig. 7g and h). In ECs, MKL1 silencing significantly inhibited 
endothelial migration (Fig. 7i). Hence, although cAMP elevation differentially affected MKL1 nuclear transloca-
tion in VSMCs and ECs, the downstream effects of MKL1 appeared to be similar.
Discussion
In this study we investigated the regulation of the SRF co-factors, MKL1 and MKL2, by cAMP signalling in 
VSMCs and ECs and the role of this mechanism in regulation of cell proliferation and migration. We demon-
strate that cAMP-induced actin-depolymerisation prevents mitogen-induced nuclear localisation of MKL1 and 
2 in VSMCs and that this mechanism underlies, at least in part, the anti-mitogenic and anti-migratory effects 
of cAMP in these cells. In detail, cAMP elevation in VSMCs using either forskolin, cAMP-analogues or phys-
iological GPCR agonists rapidly inhibited RhoA-ROCK signalling, inhibited actin polymerisation (F-actin), 
increased actin-monomer (G-actin) levels and completely prevented mitogen-induced nuclear localisation of 
both MKL1 and MKL2. Furthermore, we show that the divergent effects of cAMP on VSMC and EC prolifera-
tion and migration can be explained by differences in actin-remodelling and MKL1 and 2 cytoplasmic:nuclear 
shuttling. Although RhoA-ROCK signalling was inhibited in both cell types, stimulation of cAMP signalling in 
venous or arterial ECs did not inhibit actin polymerisation, elevate actin-monomer levels or induce exclusion of 
MKL1 from the nucleus. MKL2 was constitutively cytoplasmic in these cells. As a result, proliferation and migra-
tion of ECs was not inhibited in response to elevated cAMP or GPCR activation. In some cases, cAMP elevation 
actually stimulated EC proliferation and migration (Supplement Figs 1–3)38. Although these stimulatory effects 
were modest, they contrasted with the large inhibitory effects observed in VSMCs Previous studies have shown 
that MKL1 expression is low in healthy arteries but is elevated after wire-injury to femoral arteries in mice35. Mice 
deficient in MKL1 develop smaller injury-induced intimal lesions than their wild type counterparts and display 
attenuated atherosclerosis, suggesting that MKL1 plays a central role in vascular remodelling35. Although little 
is known about the function of MKL2 in the vascular cells, MKL2-deficient mice die in late gestation of vascular 
defects39. We now show using pharmacological and siRNA-mediated silencing that MKL1 is essential for VSMC 
and EC proliferation and migration. MKL2 also plays an important role in controlling VSMC proliferation but 
not migration. Our new data highlights the divergent effects of cAMP on actin remodelling and hence MKL1/2 
regulation between VSMCs and ECs and helps explain the opposite effects of cAMP on proliferation and migra-
tion in these cells.
Precisely how cAMP-induced actin dynamics modulates VSMC behaviour has remained poorly understood 
but likely involves actin-sensitive transcription factors. SRF activity is sensitive to RhoA-actin dynamics and 
plays a central role in controlling VSMC differentiation as well as promoting expression immediate-early genes 
RaVSMCs expressing GFP-MKL1 (h; n = 3) or GFP-MKL2 (i; n = 3) were serum starved for 4 hours before being 
stimulated for 1 hour with 10% FCS in the presence or absence of 25 µM forskolin and 1 µM Jasplakinolide, 2 µM 
Cytochalsin-D (CYTO-D) or 5 µg/ml latrunculin B (LAT-B), as indicated. Black bars indicate nuclear localisation, 
white bars cytosolic localisation and striped bars mixed localisation of MKL1/2. *Indicates p < 0.05, **indicates 
p < 0.01, ***indicates p < 0.001; One-way with replication ANOVA and Student Newman Keuls post-test.
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Figure 7. Role of MKL-1 and -2 in VSMC and EC proliferation and migration. Asynchronously proliferating 
RaVSMCs, HuVSMCs and HUVECs were treated with 20 µM CCG203971 for 24 hours. BrDU was included 
for the last 6 hours to label proliferating cells (a; n = 3). RaVSMCs were transfected with siRNA targeting 
MKL1, MKL2 or MKL1 + MKL2 and cells labelled with BrDu 48 hours after transfection (b; n = 3). HUVECs 
were infected with adenovirus expressing shRNA targeting MKL1 (Ad:shMKL1) and cells labelled with BrDu 
48 hours after infection (c; n = 3). Migration of RaVSMCs (d,e,g; n = 3), HuVSMCs (f; n = 3) and HUVECs 
(h,i; n = 3) in presence of 20 µM CCG203971 (c,e,f), transfected with siRNA targeting MKL1, MKL2 or 
MKL1 + MKL2 (h,i) or infected with Ad:shMKL1 (j) was analysed using IncuCyte real-time scratch wound 
assays. *Indicates p < 0.05, **indicates p < 0.01, ***indicates. One-way with replication ANOVA and Student 
Newman Keuls post-test (a,b,g). Student’s T-test (c). Two-way ANOVA (d,e,f,h,i).
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required for cell proliferation and migration, such as c-fos40. For example, activated RhoA mutants that promote 
actin-polymerisation induce the expression of SRF-dependent reporter genes while inhibition of RhoA with C3 
transferase blocks their induction by mitogenic stimuli41. This has led to the model where free G-actin inhibits 
SRF activity and this inhibition is relieved by Rho GTPase- mediated actin polymerisation. Alterations in actin 
dynamics appear to be necessary for the regulation of SRF by a wide range of extracellular signals, including 
growth factors, lysophophatydic acid, extracellular matrix and GPCR agonists31, 42. Treatment of cells with actin 
polymerisation inhibitors or actin polymerisation agents demonstrated that SRF activity is responsive to changes 
in the G-actin pool31. We previously demonstrated the cAMP inhibited members of the Rho GTPases, including 
RhoA and Rac1 in VSMCs19 and here we show that elevated cAMP rapidly induces loss of F-actin and an increase 
in G-actin in VSMCs but not ECs. This is associated with inhibition of SRF-dependent transcription in VSMCs 
but not ECs. In VSMCs, it is likely that reduced actin-polymerisation and the concomitant increase in G-actin 
is responsible for repression of SRF activity. Interestingly, in ECs, SRF-dependent transcription is actually stim-
ulated by elevated cAMP. The mechanism is not clear but we observed an increase in phalloidin stained cortical 
F-actin stress fibres after forskolin stimulation; although we could not detect any reduction in global G-actin. 
However, we cannot exclude the possibility that small undetectable changes in the levels or localisation of G-actin 
may be responsible for the forskolin-mediated increase in SRF activity in these cells. Nevertheless, our data clearly 
demonstrates that activation of cAMP-sensitive signalling pathways has divergent effects on actin-dynamics and 
SRF activity in VSMCs and ECs and we suggest that this is responsible, at least in part, for the opposing effects of 
cAMP on the proliferation and migration of these cells.
Why cAMP has such different effects on actin dynamics and SRF activity in VSMCs and ECs is currently 
unclear but is likely to reflect differences is the regulation of Rho GTPases in these cells. For example, we and oth-
ers previously demonstrated inhibition of RhoA and Rac1 in VSMCs in response to elevated cAMP signalling19. 
A similar inhibition of RhoA has been reported in ECs, and has been implicated in increased EC spreading and 
reduced EC barrier permeability in response to cAMP43. We detected a rapid inhibition of RhoA-ROCK signal-
ling in both VSMCs and ECs in response to elevated cAMP. However, nuclear localisation of MKL1 in VSMCs 
was ROCK-dependent but in ECs it was ROCK-independent. Our data suggests that in ECs, cortical actin and 
nuclear MKL1 is maintained by a RhoA-ROCK independent mechanism. Our data supports a role for Rac1 in 
maintaining nuclear MKL1 in ECs. In ECs, cAMP induces Rac1 activity44, 45, which is associated with increase 
cortical actin polymerisation. Inhibition of Rac1 using NSC273766 in the presence of forskolin reduces nuclear 
MKL1 levels, suggesting that Rac1-mediated cortical actin polymerisation is responsible for maintaining nuclear 
MKL1 in ECs and may, at least in part, account for our observed differences in MKL translocation between 
VSMCs and ECs.
MKL1 and MKL2 sense G-actin concentrations using their N-terminal RPEL domains and transduce sig-
nals to SRF30, 46, 47. Stimuli that inhibit Rho GTPases or actin polymerisation typically sequester MKL1 and 2 in 
the cytoplasm whereas factors that activate Rho GTPases or promote actin polymerisation induce their nuclear 
translocation and hence SRF activation. Here we show that elevated cAMP completely blocks mitogen induced 
nuclear localisation of MKL1 and MKL2 in VSMCs. In the case of MKL1, this is likely mediated by the inhibi-
tory effects of cAMP on RhoA, as forced expression of a constitutively-activated RhoA completely prevented the 
inhibitory effects of cAMP on MKL1 nuclear localisation. Although mitogens induced nuclear localisation of 
MKL2 in VSMCs and this was also blocked by cAMP, this effect was not reversed by activated RhoA, suggesting 
the involvement of different mechanisms controlling MKL1 and MKL2 cytoplasmic:nuclear shuttling in VSMCs. 
Similar differences in the regulation of MKL1 and MKL2 have been reported previously. For example, mechan-
ical force activates RhoA and induces nuclear translocation of MKL1 but not MKL2 in myofibroblasts, whereas 
both respond in a similar way to serum stimulation in these cells48. The mechanisms underlying the differences 
in MKL1 and MKL2 regulation are currently unclear and certainly warrant further research. This may reflect 
subtle differences in their regulation by different Rho GTPases or a requirement for additional factors for MKL1/2 
nuclear import, such as the previously reported role of serine-454 phosphorylation49. Interestingly, our data indi-
cates that cAMP controls both MKL1 and MKL2 by elevating G-actin in VSMCs. Depletion of G-actin completely 
reversed the effect of cAMP on both proteins, suggesting that regulatory differences lie upstream of G-actin. In 
ECs, MKL2 also displayed a different pattern of regulation to MKL1. In these cells, MKL1 was constitutively 
nuclear whereas MKL2 was constitutively cytoplasmic. Again, this may reflect a requirement for additional mech-
anisms for MKL2 nuclear localisation that are not active in ECs. Moreover, MKL1 and MKL2 were unresponsive 
to serum mitogens or cAMP elevation in ECs, remaining constitutively nuclear or cytoplasmic respectively. The 
constitutively nuclear MKL1 likely reflects the fact that G-actin levels were unaffected by cAMP in these cells and 
as discussed above, is this probably due to activation of Rac1-mediated cortical actin polymerisation.
Several lines of evidence suggest that MKL1 and MKL2 are involved in controlling proliferation and migra-
tion of other cells. For example, dual silencing of MKL1 and MKL2 in NIH3T3 cells suggested an important and 
complex role in maintaining cell cycle progression and genomic stability50. Furthermore, activation of MKL1 
using the small molecule isoxazole promoted wound closure in vivo in mice51. MKL1 and MKL2 are constitutively 
localized to the nucleus in hepatocellular and mammary carcinoma cells and their depletion suppresses migration 
and proliferation and anchorage-independent cell growth52. Double conditional deletion of MKL1 and MKL2 
in the epicardium in mice reduces epicardial cell migration53. In addition, the first generation RPEL domain 
inhibitor, CCG1423, effectively blocks intima formation in wire injured femoral arteries in mice35. However, 
depletion of MKLs in some cell types does not affect proliferation, suggesting cell-type specific effects of these 
co-factors54. Our data obtained using siRNA-mediated silencing and pharmacological inhibition now shows that 
MKL1 plays a role in promoting proliferation and migration of both VSMCs and ECs, emphasising the similar 
effects of signalling downstream of MKLs. Our study is the first to provide evidence that MKL2 also plays a key 
role in controlling VSMC proliferation. Interestingly, depletion of MKL2 in VSMCs had no effect of cell migration 
despite its clear effects on S-phase entry, suggesting functionally divergent roles of MKL1 and MKL2 in VSMCs. 
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In summary, our data indicates that cell-type specific effects on actin-cytoskeleton dynamics and subsequent 
nuclear translocation of MKLs explains, at least in part, the divergent properties of cAMP in VSMCs and ECs.
Taken together, our data help to explain the divergent effects of cAMP signalling on VSMC and EC prolifer-
ation and migration. Inhibition of actin polymerisation and MKL-dependent SRF activity underlies, at least in 
part, the inhibitory effects of cAMP on the growth and migration of VSMCs. In ECs, cAMP stimulates increased 
cortical actin polymerisation, which maintains low levels of G-actin, permits SRF activation and increases EC 
proliferation and migration. Furthermore, our data showing that MKL2 is inactive (i.e. constitutively cytoplas-
mic) in ECs but is required for VSMC proliferation suggest that MKL2 may represent a valuable target for future 
therapies designed to selectively inhibit VSMC proliferation.
Material and Methods
Materials. All chemicals were obtained from Sigma unless otherwise stated. Antibodies to MKL1 (#14760) 
and Lamin A/C (#4777) were from Cell Signalling Technologies. Antibody to GAPDH (MAB374) was from 
Millipore. Anti-BrdU antibody (B2531) was from Sigma Aldrich.
Smooth muscle and endothelial cell culture. Male Sprague Dawley rats were killed by cervical disloca-
tion in accordance with schedule 1 of the U.K. Animals (Scientific Procedures) Act 1986 and Directive 2010/63/
EU of the European Parliament and with the approval of the University of Bristol. Methods used to culture VSMCs 
and ECs are described in detail in the Supplement. Human saphenous vein VSMCs (HuVSMCs) at passage 2–8 
were generated as described previously55 from spare sections of human saphenous vein obtained with informed 
consent in all cases from patients undergoing coronary artery bypass surgery at the Bristol Royal Infirmary. All 
procedures were carried out in accordance with the ethical approval (Research Ethics Committee #04/Q2007/6) 
and the approval of the University of Bristol ethical committee. Approximately ten different batches of rat aortic 
VSMCs (RaVSMCs), six batches of human saphenous vein VSMCs (HuVSMCs), six batches of human umbilical 
vein ECs (HUVECs) and three batches of human coronary artery ECs (HCAECs) were used in these studies. All 
experiments were performed using different batches of cells that were prepared from different animals/donors.
Real-time scratch wound migration assays. Real-time analysis of migration was performed using a 
IncuCyte® ZOOM live cell imaging system (Essen BioScience) according to the manufacturer’s instructions. 
Briefly, cells were seeded (2 × 104 cells/well for RaVSMCs, 1 × 104 cells/well for HuVSMCs and 2 × 104 cells/well 
for HUVECs) into ImageLock-96 well plates. Wells were scratched using a WoundMaker® tool and phase con-
trast images of cell migration into the wounded area acquired hourly for 24 hours. Relative wound confluence was 
calculated using the Cell Migration Image analysis module of the IncuCyte® ZOOM software.
Quantitative RT-PCR and Western Blotting. Quantification of mRNA and protein levels was performed 
by RT-qPCR and western blotting respectively, as described previously56. Total RNA, extracted using Ambion 
Pure-Link kits (Thermo Fisher) and was reverse transcribed using QuantiTect RT kit (Qiagen) and random prim-
ers. Quantitative PCR was performed using Roche SYBR Green using a Qiagen Roto-Gene Q PCR machine 
(20′@95 °C; 20′@62 °C; 20′@72 °C). Primers sequences are described in Supplement Table 1. Data were normal-
ised to total RNA. Western blots were performed using a Mini-Protean II system. Proteins were transferred to 
PVDF membrane using a semi-dry Turbo blotter (Bio-Rad) and detected using ECL and a digital ChemiDoc 
imaging system (Bio-Rad).
Plasmids, siRNA and Adenoviral Vectors. Details of all plasmid and viral vectors are described in the 
Supplement. Silencer Select siRNAs were purchased from Invitrogen and are also described in the Supplement.
Transient transfection. Plasmid transfection was performed by electroporation using an Amaxa 
Nucleofector-1.5. 1 × 106 VSMCs were transfected with 3–5 μg of DNA or 100 pmoles of siRNA using the stand-
ard Nucleofector program A033.
Reporter gene luciferase assays. Cells were transfected by electroporation with the indicated promoter 
reporter plasmids together with pTk-Renilla for normalisation. Cells were stimulated with the indicated agents 
24 hours followed by lysis in Promega cell culture lysis buffer. Luciferase and Renilla activity were quantified using 
the dual reporter assay kit (Promega) according to the manufactures instructions using Glomax luminometer 
(Promega).
F:G actin ratio assays. F- and G-actin were separated by triton solubility essentially as previously37 
described with slight modifications. Following treatment, G-actin was extracted in G-actin extraction buffer 
(PBS, 10% glycerol, 0.1% triton X-100, 1 mM ATP and complete protease inhibitor) and incubated for 5 min at 
room temperature with slight agitation. Samples were centrifuged at 15,000 g at 4 °C for 5 min. The supernatant 
(soluble G-actin) was collected. Titon-X-100 insoluble material (F-actin) remaining in the wells and pelleted from 
the soluble fraction was lysed in reducing Laemmli SDS sample buffer. Samples were analysed by western blotting 
using a β-actin specific antibody (Sigma).
cAMP quantification. Intracellular cAMP levels were quantified using the cAMP direct ELISA assay 
(Abcam) according to the manufacturers instructions.
Statistical Analysis. After testing for Gaussian distribution, statistical analysis was performed using 
two-way ANOVA, one-way ANOVA with Student-Newman-Keuls post-test or where appropriate a paired stu-
dent’s t-test, as indicated. *Indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001.
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Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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